Morgan Stanley Altamira Therapeutics Ltd. Transaction History

Morgan Stanley

  • $1.35 Trillion
  • Q3 2024

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$0.27 - $120.04 $8,756 - $3.89 Million
32,431 Added 123.31%
58,731 $17,000
Q2 2022

Oct 27, 2022
BUY
$0.48 - $1.66 $8,640 - $29,880
18,000 Added 216.87%
26,300 $13,000
Q2 2022

Aug 15, 2022
BUY
$0.48 - $1.66 $8,640 - $29,880
18,000 Added 216.87%
26,300 $13,000
Q1 2022

Oct 27, 2022
SELL
$0.69 - $1.92 $12,419 - $34,560
-18,000 Reduced 68.44%
8,300 $9,000
Q1 2022

May 13, 2022
BUY
$0.69 - $1.92 $206 - $576
300 Added 3.75%
8,300 $9,000
Q4 2021

Feb 14, 2022
SELL
$1.28 - $2.4 $9,789 - $18,355
-7,648 Reduced 48.88%
8,000 $15,000
Q3 2021

Nov 15, 2021
BUY
$2.01 - $3.58 $31,452 - $56,019
15,648 New
15,648 $31,000

About Altamira Therapeutics Ltd.

CYTO Quotes by TradingView
  • Ticker CYTO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 1,009,710
  • Market Cap $172K
  • Description
  • Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, includin...
More about CYTO
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email